Patent Term Extension Application for Visterra, Inc.

The FDA published a notice on Regulations.gov announcing a patent term extension application submitted by Sterne, Kessler, Goldstein & Fox P.L.L.C. on behalf of Visterra, Inc. The application (FDA-2026-E-3826-0002) relates to a pharmaceutical patent and was filed with CDER.\n\nAffected parties include pharmaceutical and biotech companies seeking to extend patent terms for drug products under the Hatch-Waxman Act. This is a procedural filing notice; no compliance obligations or deadlines are established by this document. Stakeholders may monitor the docket for any further FDA action on the application.